Phase III intismeran results add a new growth pillar for MRK; Goldman Sachs raises price target to $160

Overview

The report focuses on intismeran, the personalized mRNA cancer therapy developed through MRK's collaboration with Moderna, analyzing how its positive Phase III melanoma results affect platform validation, MRK's long-term revenue, valuation, and the read-through for other oncology companies and programs. Goldman Sachs believes the program is shifting from an opportunity to which the market previously assigned limited value into a more credible growth pillar for MRK following Keytruda's patent expiry.

Core views

Following positive Phase III melanoma results for intismeran, MRK shares closed approximately 12.5% higher in a single day, one of the largest one-day gains in the company's history, adding about $43 billion in market capitalization; the report states that Moderna shares rose 180%, adding approximately $32 billion in market capitalization. Goldman Sachs believes MRK's larger increase in market capitalization reflects materially lower pre-results expectations for the program than for Moderna. The results not only validate the individualized neoantigen therapy platform but also prompt investors to reassess the technology's potential to expand into other early-stage solid tumors and create a more durable revenue stream. Compared with conventional drugs, such personalized therapies are viewed as facing lower risks from generic and commoditized competition. From a development and commercialization perspective, MRK believes recurrence-free survival (RFS) can serve as an appropriate endpoint for regulatory approval, with precedent from prior melanoma studies; the precise magnitude of efficacy still awaits further disclosure at a medical conference and potentially in a journal publication. On manufacturing, MRK emphasized Moderna's experience in large-scale COVID-19 vaccine production. From an accounting perspective, MRK will recognize all global sales revenue, while the two parties will share profits on a 50/50 basis. Initial indication selection focuses on cancers in which immunotherapy is already validated and that have high immune sensitivity and tumor mutational burden, including melanoma and non-small cell lung cancer. The platform's broader applicability will subsequently be tested in different tumor types, including renal cell carcinoma and muscle-invasive bladder cancer. Development is gradually shifting toward earlier-stage patients while metastatic disease continues to be explored. Goldman Sachs added intismeran to its core MRK model, forecasting global peak melanoma sales of $4.3 billion and mechanically attributing $2.15 billion to MRK based on its 50/50 economic interest. Although MRK will actually recognize global sales revenue, the model simplifies the treatment by recognizing 50% of revenue. Goldman Sachs' Moderna analysts also include $6.6 billion in non-small cell lung cancer sales, but this portion has not yet been incorporated into the core MRK forecast pending additional de-risking data. Separately, the report's formal valuation-risk section presents risk-adjusted 2035 revenue of $3.3 billion for melanoma and $5.6 billion for non-small cell lung cancer, with the economic interest likewise split equally with Moderna. Based on these changes, Goldman Sachs raises MRK's 12-month price target from $140 to $160, applying 16.0x Q5-Q8 adjusted EPS versus 14.0x previously; FY2026, FY2027, and FY2028 EPS forecasts are largely unchanged. Reasons for the multiple increase include incorporating intismeran revenue, the value of expanding the platform into more tumors, the longer revenue duration and greater resistance to generic replication, increased confidence in the post-Keytruda patent-expiry revenue trajectory, and the pharmaceutical sector's overall rerating to approximately 16x FY2027 earnings. Investors are increasingly valuing MRK using post-patent-expiry 2030 earnings multiples. The report states that MRK trades at approximately 14.5x 2030 earnings, around 1x and 3x above BMY and PFE, respectively, but Goldman Sachs believes this premium is consistent with MRK's clearer post-patent-expiry revenue trajectory. Regarding near-term events, Goldman Sachs had previously estimated that a positive intismeran update could lift MRK by approximately 7%, while noting that sentiment could drive the gain beyond that level; the actual increase was approximately 12.5%. Following the realization of this key catalyst, Goldman Sachs still views MRK's event path through the year as positive, but expects subsequent clinical updates to have a more incremental impact on the share price. The ESMO meeting in Madrid from October 23 to 26, 2026, and MRK's investor event on October 26 are key focal points. In addition to intismeran efficacy details, the market will watch the development strategy for sac-TMT in the first-line lung cancer KEYNOTE-189 population, partner Kelun's OptiTrop-Lung06 and other sac-TMT trials, and the rationale for future global trials combining sac-TMT with PD-1/VEGF. Other events include Phase III data for the immunology program tulisokibart, Phase III data for the ophthalmology program MK-3000, AZN's AVANZAR trial, and SMMT's HARMONI-3 trial. Regarding cross-coverage implications, BNTX rose 24% on the news. Goldman Sachs believes that although BNTX's iNEST platform and indications differ from the MRK/Moderna program, the results provide broader validation for personalized cancer-vaccine platforms and add optionality for BNTX beyond pumitamig and its ADC programs. BNTX's programs include autogene cevumeran, developed in partnership with Roche/Genentech; BNT113 for HPV16-positive head and neck squamous cell carcinoma; and BNT116 targeting multiple non-small cell lung cancer antigens. Enrollment in a high-risk colorectal cancer Phase II trial has been completed, and the data safety monitoring committee recommended that the trial continue without modification. The final analysis of the Phase II trial in adjuvant ctDNA-positive colorectal cancer is expected in 2027. The Phase III interim PFS analysis for BNT113 and BNT116 data at WCLC 2026 are also upcoming milestones. For BMY, Goldman Sachs expects the impact to be limited and gradual. BMY has Opdivo, Yervoy, and Opdualag in melanoma, but a substantial portion of its revenue comes from advanced metastatic disease, whereas intismeran is expected to be used primarily in earlier-stage patients. BMY stated that it remains too early to assess the impact before more details are disclosed regarding efficacy magnitude and the administration process. Convenience of administration may also affect Opdivo use, which is concentrated in community healthcare settings. Melanoma accounted for 19% of US Opdivo sales in Q2 2026. Assuming approximately $10 billion in global annual Opdivo revenue, around 20% from melanoma, and an equal split between adjuvant and metastatic treatment, the report's illustrative calculation suggests approximately $1 billion in adjuvant melanoma revenue could be at risk. The neoadjuvant Opdivo plus Yervoy regimen from the NADINA trial could provide a partial offset, but actual use remains at an early stage. MRK's explicit downside risks include faster-than-expected revenue erosion after Keytruda's patent expiry, a lower-than-expected conversion rate to subcutaneous Keytruda, further slowing in mature vaccine products, slower uptake of newly launched products, weaker-than-expected pipeline data, and deterioration in the vaccine, FDA policy, tariff, regulatory, and M&A environments. Among cross-coverage companies, BNTX also faces efficacy, safety, combination-therapy, competition, commercialization, COVID-19 vaccine, and capital-allocation risks related to BNT327 and other oncology programs. BMY faces risks from weak sales of growth products, greater patent-expiry and IRA impacts on legacy products, and unfavorable clinical or regulatory outcomes for key pipeline assets.

Analysis framework

The report first examines changes in share prices and market capitalization following the Phase III results, using the gap between expectations before and after the announcement to assess the extent of market repricing. It then incorporates regulatory, manufacturing, revenue-recognition, and indication-development information obtained through discussions with MRK to update pipeline sales forecasts and the price target. Finally, it analyzes the event path for upcoming catalysts and maps the same results across BNTX's cancer-vaccine platform and BMY's existing melanoma business.

Methodology notes

• Valuation methodologyPE/PEG valuation

  P/E valuation based on Q5-Q8 adjusted EPS

  Goldman Sachs calculates MRK's 12-month price target using 16.0x Q5-Q8 adjusted EPS, versus 14.0x previously; BMY's $63 price target applies 10.0x Q5-Q8 EPS.

• Valuation methodology

  Risk-adjusted pipeline peak-sales valuation

  The report incorporates peak revenue from different intismeran indications into the valuation based on clinical risk and partnership economics, while distinguishing among unadjusted sales opportunities, risk-adjusted revenue, and MRK's economic interest following the 50/50 split with Moderna.

• Event trading and behavioral financeEvent-driven analysis

  Clinical catalyst and event-path analysis

  The report compares the actual share-price reaction following the clinical data announcement with prior expectations and assesses the potential impact of each catalyst on expectations and valuation across milestones including ESMO and subsequent Phase II and Phase III data.

• Valuation methodologyDCF discounted cash flow

  BNTX discounted cash flow valuation

  The report values cross-covered BNTX using a DCF methodology, deriving a 12-month price target of $128 with an 11% weighted average cost of capital and a 1% terminal growth rate.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Merck & Co. (MRK.US)

  Positive Phase III intismeran results increase the credibility of a new oncology growth pillar and the post-Keytruda patent-expiry revenue trajectory.

  Strengths

  It has the Keytruda foundation, can recognize global intismeran sales revenue, and can leverage Moderna's mRNA manufacturing experience to expand into more immune-sensitive solid tumors.

  Weaknesses

  Other indications have not yet been fully de-risked, near-term EPS forecasts are largely unchanged, and subsequent clinical events are expected to have a more incremental impact.

  Comparison

  Its approximately 14.5x 2030 P/E is around 1x and 3x above BMY and PFE, respectively, but the report believes MRK has a clearer post-patent-expiry revenue trajectory.

  Risks

  Post-patent-expiry erosion of Keytruda, insufficient conversion to the subcutaneous formulation, weak vaccine and new-product performance, pipeline failures, and deterioration in the regulatory environment.

• Moderna (MRNA)

  As MRK's intismeran partner, it shares profits on a 50/50 basis and benefits from validation of the personalized mRNA cancer-therapy platform.

  Strengths

  MRK cited its experience in large-scale COVID-19 vaccine production; before the results, the market had already priced in a greater probability of success in melanoma.

  Weaknesses

  Expansion into non-small cell lung cancer and other solid tumors still requires additional de-risking data.

  Comparison

  The report states that MRNA had a larger share-price reaction, but MRK added approximately $43 billion in market capitalization that day, exceeding MRNA's approximately $32 billion.

  Risks

  Clinical efficacy in other indications and the durability of revenue still require validation from subsequent data.

• BioNTech (BNTX)

  The MRK/Moderna data are viewed as broad validation of personalized cancer-vaccine platforms, adding optionality to BNTX's related pipeline.

  Strengths

  It has multiple mRNA immuno-oncology programs, including autogene cevumeran, BNT113, and BNT116, and is exploring their use in combination with checkpoint inhibitors.

  Weaknesses

  The iNEST platform and selected indications differ from intismeran, so MRK's data cannot directly demonstrate the success of BNTX's own programs.

  Comparison

  BNTX rose 24% on the news, but its platform, indications, and development path differ from those of the MRK/Moderna program.

  Risks

  BNT327 and other oncology programs may underperform expectations in efficacy, safety, combination therapy, or commercialization, while also facing competition, COVID-19 vaccine, and capital-allocation risks.

• Bristol-Myers Squibb (BMY)

  intismeran could gradually affect the use of products such as Opdivo in earlier-stage adjuvant melanoma, but the report expects the overall impact to be limited and slow.

  Strengths

  Its melanoma portfolio includes Opdivo, Yervoy, and Opdualag, with a substantial portion of revenue derived from the advanced metastatic market that is less directly affected by intismeran; the NADINA regimen could provide a partial offset.

  Weaknesses

  The report's illustrative calculation suggests approximately $1 billion in Opdivo adjuvant melanoma revenue could be at risk.

  Comparison

  BMY has greater exposure to community healthcare and advanced metastatic treatment, whereas intismeran is expected to be used initially in earlier-stage patients.

  Risks

  Slowing growth products, intensified patent-expiry and IRA impacts on legacy businesses, and unfavorable clinical or regulatory outcomes for key pipeline assets.

Key data

• MRK one-day share-price reactionApproximately +12.5%Closing gain following the announcement of positive Phase III intismeran results
• Change in MRK market capitalizationApproximately +$43 billionThe report states this exceeded Moderna's approximately +$32 billion over the same period
• Moderna share-price reaction+180%One-day increase stated in the report
• Other cross-coverage share-price reactionsBNTX +24%; MRVI +28%; TEM +24%Corresponding respectively to cross-read-throughs for cancer vaccines, manufacturing, and diagnostics
• Global peak sales of intismeran in melanoma$4.3 billionUnadjusted peak-sales forecast used in the core MRK model
• MRK's corresponding economic interest$2.15 billionMechanically calculated based on the 50/50 profit split between MRK and Moderna
• Non-small cell lung cancer sales opportunity$6.6 billionForecast included by Goldman Sachs' Moderna team; not yet included in the core MRK forecast
• Risk-adjusted 2035 revenueMelanoma $3.3 billion; non-small cell lung cancer $5.6 billionRisk-adjusted figures presented in the report's formal valuation-risk section
• MRK price target$16012-month price target, previously $140
• MRK target valuation multiple16.0xBased on Q5-Q8 adjusted EPS, previously 14.0x
• Changes to near-term earnings forecastsFY2026/FY2027/FY2028 largely unchangedThe price-target increase is primarily driven by changes in the valuation multiple and long-term growth visibility
• MRK long-term P/EApproximately 14.5x 2030 earningsThe report states this is approximately 1x and 3x above BMY and PFE, respectively
• Pharmaceutical industry valuation benchmarkApproximately 16x FY2027 earningsIndustry median cited in the report
• Keytruda patent-expiry milestone2028intismeran is viewed as a growth pillar that improves the post-patent-expiry revenue trajectory
• MRK's expected share-price reaction before the eventApproximately +7%Goldman Sachs' prior estimate for a positive intismeran update, versus the actual reaction of approximately +12.5%
• Timing of subsequent intismeran dataRCC: 2026 or early 2027; bladder cancer and NSCLC: 2027Refers respectively to Phase II renal cell carcinoma, Phase II muscle-invasive bladder cancer, and Phase III non-small cell lung cancer
• BMY melanoma exposure19%Share of Q2 2026 US Opdivo sales derived from melanoma
• Illustrative BMY revenue riskApproximately $1 billionBased on assumptions of approximately $10 billion in global annual Opdivo revenue, around 20% from melanoma, and an equal split between adjuvant and metastatic treatment
• BNTX valuationPrice target $128; WACC 11%; TGR 1%12-month price target based on a DCF methodology
• BMY valuationPrice target $63; 10.0x Q5-Q8 EPSCurrent rating is Neutral

Impact & implications

Goldman Sachs believes the positive Phase III results transform intismeran from a potential program not fully reflected in MRK's share price into a growth pillar that can be incorporated into forecasts and valuation, while improving visibility into MRK's revenue trajectory beyond Keytruda's 2028 patent expiry. The results also provide positive validation for personalized cancer-vaccine platforms, although the value of expansion into other solid tumors still requires confirmation from subsequent data. The impact on BMY's existing melanoma business is expected to unfold slowly and be concentrated primarily in the earlier-stage adjuvant-treatment market.

Risks

• Revenue erosion following Keytruda's patent expiry could be faster than expected, and the conversion rate to subcutaneous Keytruda could also be below expectations.
• MRK's mature vaccine products could slow further, while sales uptake of newly launched products could be weaker than expected.
• Other intismeran indications and other MRK pipeline programs may fail to achieve the expected clinical results.
• The vaccine, FDA policy, tariff, regulatory, and M&A environments could be more adverse than expected.
• BNTX's BNT327 and other oncology programs face risks related to efficacy, safety, competition, commercialization, COVID-19 vaccine performance, and capital allocation.
• BMY faces risks from weak sales of growth products, accelerating erosion of legacy products, and unfavorable clinical or regulatory outcomes for key pipeline assets.

What to watch

• Watch the magnitude of intismeran's efficacy disclosed at the ESMO meeting in Madrid from October 23 to 26, 2026, as well as MRK's investor event on October 26.
• Watch for Phase II renal cell carcinoma data for intismeran in 2026 or early 2027, and Phase II bladder cancer and Phase III non-small cell lung cancer data in 2027.
• Watch for detailed sac-TMT data at ESMO, Kelun's OptiTrop-Lung06 and other trials, and evidence supporting future global trials of PD-1/VEGF plus ADC combinations.
• Watch MRK's event path, including Phase III tulisokibart, Phase III MK-3000, AZN's AVANZAR, and SMMT's HARMONI-3.
• Watch the Phase III interim PFS analysis for BNT113, BNT116 data at WCLC 2026, and the final Phase II analysis of autogene cevumeran in 2027.
• Watch changes in the actual use of intismeran and BMY's Opdivo, Yervoy, and Opdualag across adjuvant, neoadjuvant, and metastatic melanoma.